Summary: Adapting a spontaneous, genetically heterogenous T-ALL model to preclinical testing demonstrated that response to therapeutic anti-Notch1 antibodies was determined by Notch1 mutational status and that PD-1 immune checkpoint blockade alone lacked anti-tumor activity. The gene discussed is PDCD1; the disease is acute lymphoblastic leukemia.